Lifemd Inc Stock Price, News & Analysis

LifeMD (NASDAQ:LFMD), a virtual primary care services provider, reported strong Q2 2025 financial results with total revenue increasing 23% year-over-year to $62.2 million. The company's telehealth segment showed impressive growth, with revenue up 30% to $48.6 million and adjusted EBITDA surging 560% to $3.4 million.

Key operational highlights include reaching 297,000 active telehealth subscribers, launching a nationwide behavioral health offering, and acquiring a virtual women's health brand. The company generated over $8 million in operating cash flow and exited the quarter with $36.2 million in cash, having fully repaid all senior debt.

However, LifeMD revised its full-year 2025 guidance downward due to temporary challenges in its Rex MD business, now expecting total revenue of $250-255 million and adjusted EBITDA of $27-29 million, compared to previous guidance of $268-275 million and $31-33 million respectively.

Medifast (NYSE: MED) reported challenging second quarter 2025 results, with revenue declining 37.4% to $105.6 million from $168.6 million in Q2 2024. The company's active OPTAVIA coaches decreased 32.7% to 22,800, while revenue per coach fell to $4,630. Despite operational challenges, Medifast maintained a strong balance sheet with $162.7 million in cash and no debt.

Net income was $2.5 million ($0.22 per share), including a $2.0 million gain from LifeMD investment. The company faces headwinds from GLP-1 weight loss medications but highlighted positive clinical findings showing their OPTAVIA 5 & 1 Plan preserves 98% of lean mass. For Q3 2025, Medifast projects revenue between $70-90 million with EPS ranging from ($0.60) to $0.00.

LifeMD (NASDAQ:LFMD), a virtual primary care services provider, announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The event will take place at the InterContinental Boston from August 12-14, 2025.

Company management will engage in a fireside chat on August 13th at 8:30 AM ET and conduct one-on-one investor meetings during August 12-13. Interested investors can register through their Canaccord Genuity representative.

LifeMD (NASDAQ: LFMD), a virtual healthcare services provider, has announced key leadership appointments. Shayna Webb Dray, previously Senior VP of Operations, has been promoted to Chief Operating Officer. Webb Dray, who joined LifeMD in 2021, brings over 15 years of operations and supply chain experience.

The company also expanded Jessica Friedeman's role to Chief Marketing and Product Officer and promoted Jacob Ellison to Chief Analytics Officer, where he will lead data strategy and AI innovation. These appointments aim to strengthen LifeMD's operational excellence and support its expansion into new healthcare verticals.

LifeMD (Nasdaq: LFMD), a leading virtual primary care provider, has scheduled its second quarter 2025 financial results announcement for August 5, 2025, after market close. The company will host a conference call at 4:30 p.m. Eastern time.

LifeMD operates through a vertically integrated platform featuring a 50-state affiliated medical group, a 22,500-square-foot pharmacy, and a U.S.-based patient care center. The company provides telemedicine services, laboratory and pharmacy access, and specialized treatment for over 200 medical conditions, including primary care, men's and women's health, weight management, and hormone therapy.

Medifast (NYSE: MED), the company behind the OPTAVIA® health and wellness program, has scheduled its Q2 2025 financial results announcement for August 4, 2025, after market close.

The company will host a conference call at 4:30 p.m. ET featuring Chairman and CEO Dan Chard and CFO Jim Maloney. The call will be available via webcast on Medifast's Investor Relations website and will remain archived through November 3, 2025. Telephone participants can dial (201) 389-0879, with playback access available through August 11, 2025.

LifeMD (Nasdaq: LFMD), a virtual primary care services provider, has announced a quarterly dividend payment for holders of its 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP). The company will distribute a cash dividend of $0.5546875 per share. The dividend is payable on July 15, 2025, to shareholders of record as of July 3, 2025.

LifeMD (NASDAQ: LFMD), a virtual primary care services provider, has announced its participation in two major investor conferences in June 2025. The company's management will join a virtual panel discussion on "Direct to Consumer vs. Direct to Enterprise" at the BTIG Obesity Health Forum on June 18 at 2:00 PM ET. Additionally, they will participate in the Truist Securities Healthcare Disruptors & Digital Health Conference at New York City's Park Lane Hotel on June 24-25, where they will discuss "Tailored Approach to Weight Loss Solutions" and be available for one-on-one meetings with institutional investors.

LifeMD (NASDAQ: LFMD) has partnered with Novo Nordisk to launch a limited-time $299 introductory bundle for self-pay patients prescribed Wegovy®. The bundle includes Wegovy® at $199 and LifeMD's virtual weight management program, available until June 30, 2025. After the first month, the program will cost $599 monthly with no long-term commitment required.

The collaboration strengthens LifeMD's ability to deliver FDA-approved GLP-1 medications through an integrated care experience, targeting patients seeking alternatives to compounded therapies. LifeMD's platform provides comprehensive services from virtual consultation to prescription fulfillment and ongoing support. Wegovy® is available through NovoCare® Pharmacy integration for eligible uninsured patients or those whose insurance doesn't cover weight-loss medications.